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Here, we report the enhanced mucosal and systemic immunogenicity of human papillomavirus type (HPV) 16 L1 virus-like particles
(VLP) encapsidating a cytokine genetic adjuvant. Plasmid DNA expressing interleukin-2 (pIL2) was encapsidated in VLP using the
reassembly property of VLP from disassembled L1 capsomeres. pIL2 in reassembled VLP showed stability against DNase I, indicating
encapsidation. After intramuscular immunization into mice, the highest vaginal and salivary HPV16 L1-specific IgA titers were observed in
pIL2-encapsidated VLP, followed by VLP plus pIL2 in separate plasmid, and VLP alone. Similar to mucosal responses, serum IgG, IgG1,
and IgG2a antibody titers were the highest in the group treated with pIL2-encapsidated VLP. Moreover, the adjuvanticity of pIL2
encapsidated in VLP was stronger in IgG2a antibody relative to IgG1 antibody. Our results indicate that the encapsidation of a genetic
cytokine adjuvant pIL2 would be beneficial for more effective induction of mucosal and systemic immune responses to VLP vaccines.
D 2004 Elsevier Inc. All rights reserved.
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Human papillomavirus (HPV) type 16 has been known
as the most crucial pathogen in the tumorigenesis of cervical
carcinoma, the major cause of female cancer mortality in
developing countries (Tjiong et al., 2001; Waggoner, 2003).
Moreover, the sexual activity of women is well correlated
with the risk of HPV 16 infection, suggesting that sexual
contact is the most common route for HPV transmission0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.06.047
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(C.-K. Kim).(Tyring, 2000). The development of a potent vaccine
inducing HPV type 16-specific antibodies in mucosal
secretions may therefore be an efficient means to reduce
the incidence of cervical carcinoma.
Of various HPV vaccines, virus-like particles (VLP)-
based vaccines have been most widely studied for the
prevention of HPV infection of the genital tract and
associated cervical cancer. Currently, HPV16 VLP vaccines
are in clinical phase studies (Berry and Palefsky, 2003).
HPV16 VLP vaccines have advantages of relatively high
systemic immunogenicity and safety (Harro et al., 2001).
VLP vaccines mostly administered via intramuscular route,
however, still suffer from low mucosal immunogenicity. To
improve the mucosal immunogenicity of VLP, there is a
need to develop effective adjuvants.
To enhance the immune responses of various vaccines,
cytokine genetic adjuvants have been studied. Interleukin 204) 266–273
Fig. 1. Coomassie blue staining and Western blot. (a) The protein extracts
from Sf21 insect cells or recombinant baculovirus-infected Sf21 cells were
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and
visualized by Coomassie blue staining. Lane 1, recombinant baculovirus-
infected Sf21 cells; lane 2, uninfected Sf21 insect cells. (b) Separated
proteins transferred onto blot membrane were blocked and incubated with
mouse anti-HPV16 L1 CamVir-1 monoclonal antibody and alkaline
phosphatase-conjugated anti-mouse IgG antibody. Lane 3, recombinant
baculovirus-infected Sf21 cells; lane 4, uninfected Sf21 insect cells.
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most efficient genetic adjuvants. Plasmid DNA expressing
IL2 has been shown to promote the humoral and cellular
immunity of bovine viral diarrhoea virus (Nobiron et al.,
2001), human immunodeficiency virus (Moore et al., 2002),
and hepatitis B virus DNA vaccines (Du et al., 2003). In
most studies, genetic IL2 adjuvants have been separately
coadministered with antigen vaccines. However, recent
studies suggest that close association of adjuvants with
antigen may further increase the adjuvanticity. Liposomes or
nanospheres coencapsulating adjuvants and antigens have
been shown to exert higher immunogenicity as compared to
adjuvants and antigens simply coadministered in mixture
solution (Diwan et al., 2002; Li et al., 2003).
One of interesting characteristics of VLP is the capability
of self-reassembling after disassembled to L1 capsomere
components in the presence of reducing agents (McCarthy
et al., 1998). Taking advantage of the disassembly and
reassembly properties of VLP, a recent study has demon-
strated to package unrelated plasmid DNA in VLP,
suggesting the possibility of VLP as an efficient gene
transfer vehicle into cells (Touze and Coursaget, 1998).
In this study, using the self-reassembling property of
VLP, we tested whether IL2-expressing plasmid DNA could
be encapsidated in VLP and whether the encapsidation of
IL2 genetic adjuvants could potentiate the immunogenicity
of VLP vaccines. We report here that the encapsidation of
IL2-expressing plasmid DNA could significantly enhance
the induction of mucosal and systemic immune responses to
HPV16 L1 VLP vaccines.Results
Encapsidation of cytokine adjuvant pIL2 genes in VLP
HPV16 L1 protein was expressed from recombinant L1
baculovirus-infected Sf 21 cells. Western blot data showed
that the protein extracts of uninfected Sf 21 cells were not
reactive to the anti-HPV 16 L1 monoclonal antibodies
though they displayed numeral protein bands in Coomassie
blue staining (Fig. 1a). In contrast, the protein extracts of
recombinant baculovirus-infected Sf 21 cells showed a
single band of ca. 58 kDa that was reactive to anti-HPV 16
L1 monoclonal antibodies in Western blot analysis (Fig. 1b).
HPV16 L1 VLP revealed disassembly and reassembly
properties in vitro. VLP proteins purified from recombinant
baculovirus-infected Sf 21 cells showed individual particle
shape ofVLP conformation (Fig. 2a). After treatmentwith 5%
h-mercaptoethanol as a reducing agent, the particle structure
of HPV16 L1 completely dismantled (Fig. 2b). Disassembled
L1 capsomeres, however, reassembled to VLP following
removal of h-mercaptoethanol via dialysis (Fig. 2c).
Taking advantage of the disassembly and reassembly
property of VLP, a cytokine adjuvant gene pIL2 was added to
HPV L1 at the disassembled stage. After reassembly of VLP,the encapsidation of pIL2 was tested by the stability against
DNase I (Fig. 3). pIL2 encapsidated into VLP during the
reassembly process persisted in the attack of DNase I.
Meanwhile, naked pIL2 completely degraded after treatment
with DNase I. Quantitative PCR using an internal standard
plasmid of pIL2 andMicroBCA tests showed that pIL2 (0.3F
0.07 Ag) was encapsidated in 1 Ag of VLP.
Vaginal antibody responses
Vaginal IgA responses were elicited by the intramuscular
route and affected by the delivery method of adjuvant genes.
Intramuscular administration of pIL2-encapsidated VLP
induced the highest HPV16 L1 VLP-specific vaginal IgA
responses (Fig. 4a). Following ELISA tests using anti-
mouse IgA antibodies, the optical density values of the
preimmune samples were less than 0.05. Relative to PBS
vehicle treatment, the intramuscular administration of
HPV16 L1 VLP alone in PBS did not show significant
differences in vaginal IgA titers at 3 and 8 weeks after the
first immunization (Fig. 4a). The coadministration of pIL2
with VLP significantly increased vaginal IgA titers relative
to the group treated with VLP alone, showing 3.6- and 4.9-
fold increases at 6 and 8 weeks, respectively. Moreover,
compared to naked pIL2 coadministered with VLP, pIL2
encapsidated in VLP exerted significantly higher increase in
vaginal IgA titers. At 6 and 8 weeks after the first
immunization, VLP encapsidating pIL2 showed 12.5- and
20.5-fold increases in the vaginal IgA titers, respectively, in
comparison with the group treated with VLP alone (Fig. 4a).
In contrast, VLP encapsidating pVAX1 expression vector
without the IL2 gene did not show significantly different
vaginal immune responses as compared to VLP alone.
Salivary antibody responses
Salivary antibody responses were increased by the
encapsidation of adjuvant pIL2 genes in VLP. VLP
coadministered with pIL2 induced slightly higher levels of
Fig. 2. Disassembly and reassembly of VLP. Purified VLP (a), VLP treated
with h-mercaptoethanol (b), or reassembled VLP after removal of h-
mercaptoethanol (c) was applied to carbon-coated grids and stained with
2% uranyl acetate. Samples were observed by transmission electron
microscopy. Scale bar: 100 nm.
Fig. 4. Mucosal immune responses following immunization. Female
BALB/c mice were intramuscularly administered twice at 3-week intervals
with PBS or with 10 Ag of HPV16 L1 VLP in various compositions. VLP
was administered alone or coadministered with pIL2 (pIL2 + VLP) or
administered with pIL2 encapsidated inside (pIL2-encap.VLP), or admin-
istered with pVAX1 expression vector encapsidated inside (pVAX1-encap.
VLP). Antigen-specific vaginal IgA titers (a) and salivary IgA titers (b)
were determined by ELISA at 3, 6, and 8 weeks after the first vaccination.
* denotes significantly different from other groups at each time point
(AVOVA and Student–Newman–Keuls, P b 0.05). The results are
expressed as the mean F SE (n = 5).
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compared to the group immunized with VLP alone over 8
weeks after the first immunization (Fig. 4b). Similar to
vaginal IgA immune responses, the highest salivary IgA
responses were observed after encapsidation of pIL2 in
VLP. At 8 weeks following the first immunization with
pIL2-encapsidated VLP, the levels of salivary IgA anti-
bodies were 7.7- and 15.5-fold higher, in comparison with
the groups treated with VLP plus pIL2 and VLP alone,
respectively (Fig. 4b). Unlike pIL2-encpasidated VLP,
pVAX1-encapsidated VLP showed salivary IgA titers
similar to VLP alone. Similar to vaginal IgA, salivary IgA
titers were less than 60 following treatment with VLP alone
over 8 weeks.Fig. 3. Stability of VLP-encapsidated plasmid DNA against DNase I.
Disassembled L1 capsid proteins were mixed with pIL2 plasmids and
CaCl2, followed by dialysis. After treatment of reassembled VLP
encapsidating pIL2 with DNase I, plasmid DNA was extracted and
electrophoresed on a 1% agarose gel containing ethidium bromide. As a
control, naked plasmid DNA was similarly treated with DNase I. Lane 1,
molecular weight marker; lane 2, plasmid DNA initially added to the
disassembled L1 capsid proteins; lane 3, naked plasmid DNA before DNase
I treatment; lane 4, pIL2 in reassembled VLP after treatment of DNase I;
lane 5, naked plasmid DNA after treatment with DNase I.Serum antibody responses
HPV16 L1 VLP-specific serum IgG antibody responses
could be improved by encapsidation of adjuvant pIL2 gene
in VLP. The ELISA results of preimmune sample using anti-
mouse IgG antibodies were less than 0.1. Unlike mucosal
IgA antibody responses, systemic IgG antibody responses
were significantly higher in all the VLP-treated groups
relative to PBS-treated group (Fig. 5). At 3 weeks after the
first immunization, the group treated with VLP alone
revealed 4.2-fold higher levels of serum IgG antibodies as
compared to PBS-treated group. Notably, coadministration
of VLP with separate pIL2 plasmid did not significantly
differ from the group treated with VLP alone in the
induction of serum IgG responses more than 8 weeks.
However, the encapsidation of pIL2 in VLP revealed a
Fig. 5. Systemic immune responses after intramuscular administration.
Female BALB/c mice were intramuscularly administered twice at 3-week
intervals with PBS or with 10 Ag of HPV16 L1 VLP in various
compositions. VLP was administered alone or coadministered with pIL2
(pIL2 + VLP) or administered with pIL2 encapsidated inside (pIL2-
encap.VLP) or administered with pVAX1 expression vector encapsidated
inside (pVAX1-encap.VLP). Antigen-specific serum IgG titers were
determined by ELISA at days 3, 6, and 8 weeks after the first vaccination.
* denotes significantly different from other groups at each time point
(AVOVA and Student–Newman–Keuls, P b 0.05). The results are
expressed as the mean F SE (n = 5).
 
 
Fig. 6. IgG subtype antibody responses following immunization. Female
BALB/c mice were intramuscularly administered twice at 3-week intervals
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physical mixture of VLP and pIL2, and VLP alone. At 8
weeks following the first immunization of pIL2-encapsi-
dated VLP, the serum IgG levels were 7.0 and 15.7 times
higher in comparison with the serum IgG levels of the group
that received VLP plus pIL2 and VLP alone, respectively.
Moreover, the group immunized with pIL2-encapsidated
VLP exhibited serum IgG levels 13.6-fold higher than the
group treated with pVAX1-encapsidated VLP at 8 weeks
after the first immunization.
Although the immunization with VLP alone showed
higher levels of serum IgG1 responses than IgG2a
responses, the subtype antibody-inducing effects of pIL2-
encapsidated VLP were more pronounced in IgG2a rather
than in IgG1 subtype antibodies. At 8 weeks after the
immunization with VLP alone, serum IgG1 responses were
7.7-fold higher than IgG2a responses. VLP encapsidating
pIL2 increased IgG1 titer values 3.9-fold in comparison
with the group that received VLP alone at 8 weeks after
the first immunization (Fig. 6a). In contrast, VLP-
encapsidating pIL2 enhanced IgG2a titer values 23.5-fold
relative to VLP alone (Fig. 6b). The ratio of IgG1 to IgG2a
antibody levels was 1.28:1 at 8 weeks after immunization
with pIL2-encapsidated VLP.with PBS or with 10 Ag of HPV16 L1 VLP in various compositions. VLP
was administered alone or coadministered with 100 Ag of pIL2 (pIL2 +
VLP) or administered with pIL2 (3 Ag) encapsidated inside (pIL2-encap.
VLP). Antigen-specific serum IgG1 (a) and IgG2a (b) titers were determined
by ELISA at 3, 6, and 8 weeks after the first vaccination. * denotes
significantly different from other groups at each time point (AVOVA and
Student–Newman–Keuls, P b 0.05). The results are expressed as the
mean F SE (n = 5).Discussion
In this study, we demonstrated the mucosal adjuvanticity
of cytokine IL2 gene in VLP vaccines. Moreover, we
showed that the encapsidation of IL2 genetic adjuvant couldsignificantly enhance the mucosal and systemic immunoge-
nicity of HPV16 L1 VLP vaccines.
We confirmed the encapsidation of pIL2 in VLP by
stability against DNase . The stability of pIL2 encapsidated
in VLP against DNase I might be attributed by the
protection of plasmid DNA from the environment via
capsid protein L1. Our result is in accordance with recent
finding of other groups who observed the stability of
pCMV/h-gal packaged in VLP against nucleases (Touze
and Coursaget, 1998). The previous study has pointed that
the sizes of plasmid DNA could limit the encapsidation in
VLP. To reduce the size of IL2-expression plasmid, we used
relatively small size expression vector pVAX1 (3.0 kb,
Invitrogen, CA, USA) in this study. Moreover, the
encapsidation of pIL2 in VLP appears to be due to the
presence of putative DNA binding sequences of HPV16 L1
proteins. A recent study has shown that insertion of a DNA
packaging sequence of HPV16 L1 into a rabbit hemorrhagic
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capability to the particle (El Mehdaoui et al., 2000).
We observed that intramuscular immunization of HPV16
L1 VLP alone could not effectively induce mucosal IgA
antibodies. Our previous study has shown that intramuscular
administration of HPV16 L1 VLP may induce vaginal and
salivary IgA antibodies with titer values higher than 100 at 6
weeks after the first immunization with VLP (Park et al.,
2003). The discrepancy between the studies might be
explained by the different intramuscular doses of VLP. In
this study, we used 10 Ag for intramuscular administration
whereas we previously used 100 Ag for fair comparison with
intravaginally administered VLP. The vaginal IgA titer
values observed at 6 weeks after the first immunization with
pIL2-encapsidated VLP (10 Ag) were even more than 2-fold
higher than the previously reported immune responses at 6
weeks after the first immunization with VLP (100 Ag).
Unlike HPV16 L1 VLP alone, pIL2-encapsidated HPV16
L1 VLP exerted vaginal IgA responses after intramuscular
administration. Though the induction of vaginal IgA has
been generally considered to be less efficient following
intramuscular administration, recent studies report the
induction of mucosal IgA following intramuscular immuni-
zation. The induction of mucosal responses after intra-
muscular delivery of human immunodeficiency virus type 1
DNA vaccines has been reported in a primate model
(Bagarazzi et al., 1999). Moreover, Liu et al. (1998) have
reported that mucosal immune responses could be generally
comparable following intramuscular or nasal delivery of
papillomavirus-like particles. Our and others’ observations
imply that it might be possible to enhance the mucosal
immunity of HPV16 L1 VLP following intramuscular
administration via the use of effective adjuvant codelivery
method such as encapsidation.
Our results showed that both mucosal and systemic
immune responses could be most effectively potentiated by
encapsidation of pIL2 in VLP. The mechanisms by which
VLP encapsidating pIL2 exerted higher immunogenicity
than VLP alone or VLP plus pIL2 need to be further
investigated. However, the possibility exists that the
improved immune responses to pIL2-encapsidated VLP
might be partially attributed to the expression of pIL2 in the
same antigen-presenting cells where VLPs were taken up
and processed. It is speculated that the codelivery of
adjuvant and antigen to the same cell may lead to the
increased immunogenicity of antigen. The entrapment of an
adjuvant and antigen in nanospheres is a more efficient
approach for immunization than the coadministration of the
adjuvant and antigen in solution (Diwan et al., 2002).
Another possibility for the enhanced immunogenicity of
pIL2-encapsidated VLP is the stabilization of pIL2 inside
VLP. Recently, we have demonstrated the enhanced
adjuvanticity of pIL2 stabilized by complexation to a
polycationic polymer polyethylenimine (Oh et al., 2003).
It is unlikely that the enhanced immune responses of
VLP encapsidating pIL2 might be due to plasmid vectorbackbone. We observed that VLP encapsidating pVAX1
plasmid backbone did not significantly increase the mucosal
and systemic immune responses of VLP (Figs. 4 and 5). The
lack of enhanced immune responses following treatment
with VLP encapsidating pVAX1 expression vector supports
that the increased immune responses of VLP encapsidating
IL2 gene might be contributed to the IL2 moiety rather than
general plasmid DNA constructs.
Our observation that pIL2 encapsidated in VLP showed
more potent adjuvanticity in the induction of IgG2a antibody
rather than IgG1 antibody agrees with previous studies. In
bovine viral diarrhoea virus vaccines, IL2 has been shown
to enhance the IgG2a antibody higher than IgG1 antibody
(Nobiron et al., 2000). IL2 genetically fused to pneumo-
coccal surface adhesin A has been demonstrated to elicit
substantial amounts of IgG2a in addition to IgG1 (Gor et al.,
2002). IL-2-secreting recombinant bacillus Calmette Guerin
vaccine has shown higher IgG2a: IgG1 antibody ratios
relative to normal bacillus Calmette Guerin vaccine (Young
et al., 2002).
Previously, the challenge tests to study the protective
antiviral immunity of papillomavirus vaccines have been
reported in rabbits using rabbit oral papillomavirus (Embers
et al., 2002) or cottontail rabbit papillomaviruses (Leachman
et al., 2002). In case of mice, tumor models have been used
to test the anti-tumor immunity of HPV16 VLP (Revaz et
al., 2001). A transgenic mouse model has been reported for
evaluation of E6 and E7 antitumor efficacy (Eiben et al.,
2002), but not for antiviral protective immunity. One
feasible method to test the antiviral immunity of HPV in
the mice model would be to construct a recombinant virus
expressing HPV L1 antigen. Indeed, Mata et al. (2001)
tested the protective immunity of a recombinant Listeria
monocytogenes expressing a human immunodeficiency
virus protein by challenging mice with a recombinant
vaccinia virus expressing the antigen of human immunode-
ficiency virus.
In conclusion, the encapsidation of a cytokine adjuvant
gene pIL2 might be a useful strategy in enhancing mucosal
and systemic immune responses to an HPV16 L1. More-
over, the genetic adjuvant-encapsidation strategy might be
further applied to other viral vaccines forming virus-like
particles and showing disassembly and reassembly proper-
ties in vitro.Materials and methods
Plasmid DNA
pVAXmIL2 plasmid DNA (pIL2, Oh et al., 2002),
constructed by inserting murine IL2 gene into pVAX1
expression vector (Invitrogen), was amplified using Esche-
richia coli DH5a and purified using a Qiagen Giga Prep kit
(Qiagen, CA, USA). The purity of DNA preparations was
confirmed on a 1% agarose gel. All plasmid preparations
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milligram of purified DNA by the limulus amebocyte lysate
assay (Sigma, MO, USA).
Preparation of HPV16 L1 VLP
HPV16 L1 VLPs were prepared according to a method as
described previously (Kirnbauer et al., 1992). HPV16 L1
proteins were expressed in Sf21 insect cells (2  106 cells/
ml) infected with recombinant baculovirus encoding the L1
open reading frame (Park et al., 2003). At 4 days after
infection, the cells were harvested and resuspended in ice-
cold phosphate-buffered saline (PBS). The cells were then
sonicated three times for 15-s bursts using a cell disrupter
(Fisher Scientific, NH, USA). Clarified lysates were
centrifuged at 106300  g for 2 h 41 min at 4 8C
(Beckman SW 41, USA). CsCl gradient fractions were
harvested and analyzed by immunoblot. Fractions contain-
ing HPV16 L1 proteins were dialyzed in PBS and
centrifuged for 30 min at 6000  g through a Centricon-
30 microconcentrator (Millipore, MA, USA). The amounts
of purified VLP were determined using a MicroBCA kit
(Pierce, IL, USA).
Western blot
The protein extracts from Sf21 insect cells or recombi-
nant baculovirus-infected Sf21 cells were separated by 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and visualized by Coomassie blue staining.
Separated proteins were electrotransferred onto a nitro-
cellulose membrane in a transfer buffer (50 mM Tris-glycin
pH 9.0, 20% methanol) for 10 h at 20 mA. Blot membrane
was blocked and incubated with mouse anti-HPV16 L1
CamVir-1 monoclonal antibody (1:1000, RDI, NJ, USA).
After several washings, the membrane was incubated with
alkaline phosphatase-conjugated anti-mouse IgG antibody
(1:2000, Pierce).
Electron microscopy
Protein samples were allowed to settle on glow-dis-
charged carbon-coated grids, blotted dry, and stained with
2% uranyl acetate. The grids were examined by a trans-
mission electron microscope (Hitach H-600, Japan) at
165000 magnification.
Encapsidation of pIL2 in VLP
pIL2 or pVAX1 was encapsidated into VLP during the
reassembly process. For disassembly, purified HPV16 VLP
(100 Ag) was incubated in PBS with 5% of h-mercapto-
ethanol for 16 h at 4 8C. The disassembled L1 capsomere
proteins were mixed with 100 Ag of pIL2 plasmids and 2
mM CaCl2. For reassembly, the mixtures were dialyzed
against PBS containing 0.5 M NaCl for 24 h at 4 8C. Toeliminate unencapsidated plasmid DNA, the mixture was
treated with DNase I (300 U/ml) for 40 min at 37 8C. To
confirm the presence of encapsidated pIL2 in VLP, DNase I-
treated VLPs were further incubated at 55 8C with 1 mg/ml
of proteinase K (Sigma). Plasmid DNA was obtained by
phenol/chloroform extraction and ethanol precipitation.
Purified pIL2 was digested using NheI restriction enzyme
and the linearized DNA was electrophoresed on a 1%
agarose gel containing 0.1 Ag/ml ethidium bromide. The
encapsidated amounts of pIL2 in VLP were determined by
quantitative polymerase chain reaction using an internal
standard mutant plasmid of pIL2 as described previously
(Oh et al., 2002). The amounts of reassembled VLP were
measure using a MicroBCA kit (Pierce).
Animals
Female BALB/c mice were supplied from the Exper-
imental Animal Center of Seoul National University (Seoul,
South Korea). Mice were used at 6–8 weeks of age. Animals
received food and water ad libitum and were kept under
standard pathogen-free conditions. SNU guidelines for the
care and use of laboratory animals have been observed.
Immunization of mice
Female BALB/c mice received intramuscular immuniza-
tion with VLP (10 Ag/mouse) in various compositions. For
immunization, mice were intramuscularly administered with
50 Al of sterile VLP, VLP plus pIL2 (100 Ag/mouse), VLP
encapsidating pIL2 (3 Ag/mouse), or with VLP encapsidat-
ing pVAX1. Control mice received PBS vehicle only. Mice
were boosted by the same routes with equal amounts of
VLP and adjuvants on day 21.
Collection of sera and secretions
Preimmune samples of sera and secretions were obtained
1 day before immunization (day 0). Subsequent to immu-
nization, collections were made at weeks 3, 6, and 8. Serum
samples were obtained by centrifugation of blood collected
from the tail vein using a capillary tube with 1.1-mm
diameter. Salivary samples were collected using a pipetter
fitted with a plastic tip after stimulation of salivary flow by
intraperitoneal injection of pilocarpine hydrochloride
(Sigma) at a dose of 1 Ag/g mouse (Mora and Tam,
1998). Vaginal secretions were collected by washing the
tracts with 30 Al of sterile PBS. The salivary and vaginal
secretions were cleared by centrifugation at 10000  g to
remove any tissue and cellular debris. All the samples were
stored at 70 8C until analysis.
Evaluation of antibody production
The levels of HPV L1-specific antibodies were measured
using a method described by Gu¨rsel et al. (1999) with slight
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protein (1 Ag/ml) and incubated at 4 8C overnight. The
plates were washed and blocked with 2% (w/v) bovine
serum albumin. Serially diluted mouse sera, saliva secre-
tions, or vaginal washings (60 Al/well) were added and
incubated at room temperature for 2 h. Following washings,
peroxidase-conjugated goat anti-mouse IgG antibody
(1:5000, ICN, OH, USA) or goat anti-mouse IgA antibody
(1:2500, ICN) was added. After 1 h of incubation and
subsequent washing, 1-Step Turbo TMB-ELISA (3, 3V, 5,
5V-tetramethyl benzidine substrate solution, Pierce) was
added. Color development was determined spectrophoto-
metrically at 450 nm. Results were expressed as reciprocal
numbers of the final detectable dilution.
Statistics
Statistical analysis of data was conducted with a one-way
analysis of variance (ANOVA) followed by a post hoc
Student–Neuman–Keuls multiple comparison test. A P
value of less than 0.05 was considered significant.Acknowledgments
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